Inhibikase Therapeutics Inc at Sachs Associates Neuroscience Innovation Forum (Virtual) Transcript
Well, good afternoon. I want to thank the organizers of the Sachs neuroscience conference for inviting Inhibikase to present some of its early clinical and mechanistic insights into Parkinson's disease. We are a publicly listed company on the NASDAQ with the symbol IKT. And what I'll be discussing today are therapies in clinical development to reverse the progression of Parkinson's disease in human patients, something that we recognize is a bold statement to make, but we'll try to illustrate why we think such therapeutic outcomes may be possible.
I just need to make a disclosure on the next slide, related to the fact that I'm making forward-looking statements. We have a number of public filings, and I encourage anyone interested to learning more about the company to review those filings in their entirety.
As an overview, Parkinson's disease is a very large market. We expect the Parkinson's disease market to double over the next few years. It is already a $6 billion-plus sales market. And the country with the largest
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
